Interferon treatment in patients with hypereosinophilia

Most of the primary conditions with eosinophilia have now been characterized by clonality in 2008 by the WHO classification, which thereby provide a basis for separation of patients who may benefit a targeted therapy, i.e. by tyrosine kinase inhibition--and who may not. Treatment with interferon-α w...

Full description

Saved in:
Bibliographic Details
Published inCurrent drug targets Vol. 12; no. 3; p. 429
Main Author Bjerrum, Ole Weis
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.03.2011
Subjects
Eosinophilia - drug therapy
Eosinophilia - immunology
Eosinophilia - metabolism
Eosinophils - drug effects
Humans
Immunologic Factors - pharmacology
Immunologic Factors - therapeutic use
Interferon-alpha - pharmacology
Interferon-alpha - therapeutic use
Leukopoiesis - drug effects
Online AccessGet more information

Cover

More Information
Summary:Most of the primary conditions with eosinophilia have now been characterized by clonality in 2008 by the WHO classification, which thereby provide a basis for separation of patients who may benefit a targeted therapy, i.e. by tyrosine kinase inhibition--and who may not. Treatment with interferon-α was introduced some 20 years ago and still has a role in subsets of patients, which is evident from this review of casuistic reports of treatment. However, controlled, randomized, prospective, clinical trials in multi-center studies are needed to clarify dosages, monitoring, prognosis and perhaps combination therapies with interferon-α, i.e. antibodies or other immune suppressants, in the rare patients with primary eosinophilia.
ISSN:1873-5592
DOI:10.2174/138945011794815211